A Phase I/II Randomized, Double-Masked, Multicenter Clinical Trial Designed to Evaluate the Safety and Exploratory Efficacy of SF0166 Topical Ophthalmic Solution in the Treatment of Diabetic Macular Edema (DME)
Phase of Trial: Phase I/II
Latest Information Update: 06 Jun 2017
At a glance
- Drugs SF 0166 (Primary)
- Indications Diabetic macular oedema
- Focus Adverse reactions; Therapeutic Use
- Sponsors SciFluor Life Sciences
- 30 May 2017 Status changed from active, no longer recruiting to completed.
- 04 Apr 2017 Planned primary completion date changed from 1 Apr 2017 to 1 May 2017.
- 04 Apr 2017 Status changed from recruiting to active, no longer recruiting.